Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28100539 | 0.83 | CTSK (0.42) | — | |
| SCHEMBL86328 | 0.83 | TDP1 (0.38) | CHRNB2CHRNA4AAK1HDAC1HDAC2 | |
| SCHEMBL6514198 | 0.83 | TDP1 (0.38) | CHRNB2CHRNA4AAK1HDAC1HDAC2 | |
| SCHEMBL12734615 | 0.83 | CTSK (0.42) | — | |
| SCHEMBL12734604 | 0.83 | CTSK (0.42) | — | |
| SCHEMBL14280298 | 0.82 | KDM4E (0.39) | CHRNB2CHRNA4AAK1HDAC1HDAC2 | |
| SCHEMBL24881082 | 0.80 | CA1 (0.38) | CHRNB2CHRNA4AAK1HDAC1HDAC2 | |
| SCHEMBL618047 | 0.80 | CHRNB2 (0.37) | CHRNB2CHRNA4AAK1HDAC1HDAC2 | |
| SCHEMBL23773855 | 0.80 | CHRNB2 (0.37) | CHRNB2CHRNA4AAK1HDAC1HDAC2 | |
| SCHEMBL14280299 | 0.78 | AAK1 (0.33) | CHRNB2CHRNA4AAK1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207939-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207939-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | CHRNB2 3726/4885CHRNA4 854/4885AAK1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.